Directorate General of Trade Remedies, Ministry of Commerce & Industry Department of Commerce vide its notification dated 29th January, 2019 in its Sunset Review of the anti-dumping duty on imports of Paracetamol originating in/exported from China PR have concluded that domestic Industry failed to provide any satisfactory evidence that the expiry of the said anti-dumping duty is not likely to lead to recurrence injury to the domestic industry. Therefore, the Authority does not recommend continuation of the anti-dumping duty on the imports of paracetamol goods from China PR.
The original investigation concerning imports of paracetamol from China PR was initiated by the Authority vide Notification No. 60/1/2000 – DGAD dated 30th January, 2001. The Authority in the final findings, definitive antidumping duty was imposed by the Department of Revenue vide Notifications No. 29/2002 Customs dated 27th March, 2002. Since then two sunset reviews were made one in July 2007 and another in August 2013 and the ADD continued.
The Authority issued a Notification. No. 07/16/2018-DGAD dated 24th May, 2018, initiating a Sunset Review investigation once again to review the need for continued imposition of the duties and to examine whether the expiry of such duty is likely to lead to continuation or recurrence of dumping and injury to the domestic industry. The validity of the anti-dumping duty on the imports of paracetamol from China PR was extended by the Central Government up to 24th May 2019 vide Notification No. 39/2018-Customs (ADD) dated 20th August, 2018.
The Authority notes that the investigation was initiated and notified to all interested parties and adequate opportunity was given to domestic industry, exporters, importers, users and other interested parties to provide relevant information on the aspect of dumping, injury and causal link. Having initiated and conducted the investigation into dumping, injury, causal link and likelihood of dumping post cessation of ADD in force in terms of the provisions laid down under the Anti-Dumping Act and Rules, the Authority holds that further imports of paracetamol from China PR is not likely to lead to any injury to the domestic industry and therefore, the Authority does not recommend continuation of the anti-dumping duty on the imports of subject goods from China PR.